Table 3:

Baseline characteristics per study group illustrated as proportions and interquartile ranges

Characteristic	Budesonide Group N=20	Control Group N=20
Age	57 (42–64)	56 (44–63)
Gender (Male)	13 (65%)	13 (65%)
Race
White	17 (85%)	17 (85%)
African American	2 (10%)	1 (5)
Hispanic	1 (5%)	2 (10%)
Etiology of Liver Disease
Non-alcoholic steatohepatitis	6 (30%)	7 (35%)
Viral Hepatitis	6 (30%)	3 (15%)
Alcohol	6 (30%)	3 (15%)
Primary sclerosing or biliary cholangitis	2 (10%)	3 (15%)
Other	0	4 (20%)
Median MELD-Naǂ at liver transplant	23 (17–28)	22 (19–27)
Acute on chronic liver failure	4 (20%)	3 (15%)
History of portal venous thrombosis prior to Liver Transplantation	4 (20%)	4 (20%)
Hepatocellular carcinoma	4 (20%)	1 (5%)
Portal vein thrombectomy performed at the time of transplantation	3 (15%)	2 (10%)
Median Tacrolimus trough level over 24 weeks (ng/mL)	7.8 (6.5–9.4)	8 (7–9)
Hepatic artery thrombosis	0	1 (5%)

^ǂMELD-Na, Model for End Stage Liver Disease with Sodium